Loading...
•
Sep 30, 2020
Fulcrum Therapeutics Q3 2020 Earnings Report
Reported business highlights and financial results for the third quarter of 2020.
Key Takeaways
Fulcrum Therapeutics reported progress in their ReDUX4 trial and are on track to begin dosing Phase 1 trial with FTX-6058 for sickle cell disease before YE 2020. They also announced key appointments to the management team and reported a cash runway into 2Q 2022.
ReDUX4 trial progressing with full data expected in 2Q 2021.
On track to begin dosing Phase 1 trial with FTX-6058 for sickle cell disease before YE 2020.
Cash runway into 2Q 2022.
Key appointments to management team.
Forward Guidance
Fulcrum Therapeutics expects that its existing cash, cash equivalents, and marketable securities will be sufficient to enable it to fund its operating expenses and capital expenditure requirements into the second quarter of 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...